Tamoxifen

First-generation triphenylethylene SERM and the original SERM — FDA-approved 1977 for invasive breast cancer, then DCIS adjuvant and chemoprevention in high-risk women. Off-label male use: PCT (post-AAS HPG-axis restoration), gynecomastia treatment, BRCA prevention. Mechanistically a CYP2D6 prodrug — efficacy depends on conversion to endoxifen, which means CYP2D6 poor metabolizers and patients on paroxetine/fluoxetine/bupropion lose much of the antiestrogen effect. For Dylan: NOT-RELEVANT, HIGH confidence. No breast cancer, no AAS use, no gynecomastia, intact HPG axis. Documented because the AAS/PCT and male-gyno literature funnels through tamoxifen as the historical first-line SERM.

Tamoxifen is the prototype first-generation triphenylethylene SERM, synthesized at ICI Pharmaceuticals (now AstraZeneca) in the 1960s as a failed contraceptive that turned out to be a breast cancer drug. It is the molecule against which all subsequent SERMs (raloxifene, toremifene, clomiphene, enclomiphene, ospemifene, bazedoxifene) are compared.

Tissue-selective ER activity:

• Breast tissue (ERα): antagonist — blocks endogenous estradiol from binding breast ER, prevents proliferation. Mechanism of FDA-approved breast cancer treatment, DCIS adjuvant therapy, and chemoprevention indications. In men, this is the mechanism of off-label gynecomastia treatment.
• Uterus / endometrium: partial agonist — stimulates endometrial proliferation, raising risk of endometrial hyperplasia and endometrial cancer ~2-3× in postmenopausal women. Signature differentiator from raloxifene, which is endometrial-neutral/antagonist. (Irrelevant in men.)
• Bone: agonist — preserves BMD in postmenopausal women, similar to raloxifene's bone effect. Less robust evidence than raloxifene for fracture prevention but mechanistically supportive.
• Liver / lipids: agonist — modest LDL reduction, modest HDL preservation, neutral triglycerides. Estrogen-mimetic at hepatic LDL receptor.
• Hypothalamus / pituitary: partial antagonist — partial blockade of ER-mediated negative feedback → modest LH/FSH/T elevation in men. This is the mechanism of off-label PCT (post-cycle therapy) use for restarting the HPG axis after AAS-induced suppression.
• Vasomotor / thermoregulatory: variable antagonist — produces hot flushes, more severe than raloxifene in head-to-head (STAR trial).
• Coagulation: pro-thrombotic — estrogen-mimetic on coagulation factors. Increases VTE/DVT/PE risk ~2-3× over baseline; less than raloxifene in head-to-head (STAR trial) — about 30% lower thromboembolic event rate vs. raloxifene in postmenopausal women, an important nuance often missed.
• Eye / lens: dose-dependent cataract risk — long-term use (years) associated with elevated cataract incidence. Higher in tamoxifen than raloxifene per STAR trial.

CYP2D6 prodrug pharmacology — the most clinically critical PK detail:

Tamoxifen itself has only modest direct breast ER affinity. The active species are its metabolites:

• 4-hydroxytamoxifen (CYP2D6 + CYP3A4 oxidation): ~30-100× higher ER affinity than parent tamoxifen, but produced in small amounts.
• Endoxifen (4-hydroxy-N-desmethyltamoxifen) (CYP2D6 oxidation of N-desmethyltamoxifen): ~100× higher ER affinity than parent, produced in much higher steady-state plasma concentrations than 4-hydroxytamoxifen. Endoxifen carries most of the clinical antiestrogen activity in breast tissue.

Implication: CYP2D6 activity is rate-limiting for endoxifen production. CYP2D6 poor metabolizers (~7-10% of Caucasians, lower in other populations) produce significantly less endoxifen and have measurable reduction in tamoxifen efficacy for breast cancer recurrence — multiple retrospective cohort studies suggest worse outcomes in CYP2D6 PMs, though prospective dosing-adjustment trials are mixed (Goetz 2018 Breast Cancer Res Treat). Drugs that inhibit CYP2D6 (paroxetine, fluoxetine, bupropion, duloxetine, cinacalcet, quinidine) reduce endoxifen levels and may impair efficacy — paroxetine + tamoxifen co-prescription has been associated with elevated breast cancer mortality in cohort studies (Kelly 2010 BMJ).

Pharmacokinetics:

• Oral bioavailability: ~30-40% (oral absorption adequate)
• T-max parent tamoxifen: ~5 hours
• Plasma half-life parent: ~5-7 days (very long — supports once-daily dosing with steady state at ~4 weeks)
• Endoxifen half-life: ~14 days at steady state (extremely long)
• Protein binding: >98% (albumin)
• Metabolism: CYP3A4 (parent → N-desmethyl), CYP2D6 (key step → endoxifen), CYP2C9, CYP2C19 minor pathways. Phase II glucuronidation by UGT1A4, UGT2B15.
• Excretion: predominantly biliary/fecal, minor urinary
• Steady-state: ~4 weeks of daily dosing at 20 mg